Apoptotic defects are frequently associated with poor outcome in pediatric acute
lymphoblastic leukaemia (ALL) hence there is an ongoing demand for novel strategies that …

Despite progress in the treatment of acute myelogenous leukaemia (AML) the outcome often
remains poor. Tumour necrosis factor related apoptosis‐inducing ligand (TRAIL) is a …

Background: TRAIL (TNF-related apoptosis inducing ligand) exhibits selective proapoptotic
activity in multiple tumor types, while sparing normal cells. This selectivity makes TRAIL an …

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising new
treatment for the hematological malignancies. TRAIL induces apoptosis by binding to its two …

Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is a pro-apoptotic ligand
that has shown the exquisite ability to trigger extrinsic apoptosis in various types of cancer …

Activation of the TNF-related apoptosis-inducing ligand (TRAIL) pathway can induce
apoptosis in a broad range of human cancer cells. Four membrane-bound receptors have …

The cytokine TRAIL (tumor necrosis factor α-related apoptosis-inducing ligand) as well as
agonistic antibodies that bind to the TRAIL receptors, death receptor 4 (DR4) and DR5, are …

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) acts as an apoptosis
inducer for cancer cells sparing non-tumor cell targets. However, several phase I/II clinical …

BACKGROUND AND OBJECTIVES: The tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL) is regarded as a potential anticancer agent. However, many cancer cells are …

Tumour necrosis factor-related apoptosis-inducing ligand or Apo2 ligand (TRAIL/Apo2L) is a
member of the tumour necrosis factor (TNF) superfamily of cytokines that induces apoptosis …